Sushant Patkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sushant Patkar has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie A. Harmon
Artificial Intelligence Resource (AIR), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
18 shared publications - Baris Turkbey
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
17 shared publications - Eytan Ruppin
Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
17 shared publications - Peter L. Choyke
Artificial Intelligence Resource (AIR), National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
17 shared publications - Amy K. LeBlanc
Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
15 shared publications - Gregory Thomas Brown
Molecular Imaging Branch, National Institutes of Health, Bethesda, Maryland, USA
15 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade
- 17 November 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade
- Open Access
OncoBERT: Context-Aware Modeling of Somatic Mutations for Precision Oncology
Somatic mutation profiling is central to cancer diagnosis and treatment selection. However, most studies focus on individual actionable mutations, overlooking the broader mutational context that shapes tumor evolution and treatment response. Here, we introduce OncoBERT, a language model that learns contextual representations of somatic mutations from large-scale clinical sequencing data spanning >210,000 patients, 113 cancer types and 20 institutions. OncoBERT uncovers robust patient-specific mutational subtypes across diverse cohorts and targeted sequencing panels, revealing clinically meaningful mutation patterns that are associated with differential response to chemotherapy, targeted therapies, and immunotherapy. Importantly, integrating OncoBERT’s contextual representations with clinically approved biomarkers of immunotherapy response, such as tumor mutational burden (TMB) and microsatellite instability (MSI), significantly improved prediction of clinical benefit. By further incorporating matched tumor transcriptomic profiles, we linked OncoBERT-defined mutational subtypes to distinct cancer hallmark programs and tumor microenvironment states. Together, OncoBERT provides a scalable framework for deciphering somatic mutational landscapes, enabling improved patient stratification and advancing precision oncology.
Open AccessOncoBERT: Context-Aware Modeling of Somatic Mutations for Precision Oncology
Somatic mutation profiling is central to cancer diagnosis and treatment selection. However, most studies focus on individual actionable mutations, overlooking the broader mutational context that shapes tumor evolution and treatment response. Here, we introduce OncoBERT, a language model that learns contextual representations of somatic mutations from large-scale clinical sequencing data spanning >210,000 patients, 113 cancer types and 20 institutions. OncoBERT uncovers robust patient-specific mutational subtypes across diverse cohorts and targeted sequencing panels, revealing clinically meaningful mutation patterns that are associated with differential response to chemotherapy, targeted therapies, and immunotherapy. Importantly, integrating OncoBERT’s contextual representations with clinically approved biomarkers of immunotherapy response, such as tumor mutational burden (TMB) and microsatellite instability (MSI), significantly improved prediction of clinical benefit. By further incorporating matched tumor transcriptomic profiles, we linked OncoBERT-defined mutational subtypes to distinct cancer hallmark programs and tumor microenvironment states. Together, OncoBERT provides a scalable framework for deciphering somatic mutational landscapes, enabling improved patient stratification and advancing precision oncology.
- Open Access
Towards interpretable molecular and spatial analysis of the tumor microenvironment from digital histopathology images with HistoTME-v2
The tumor microenvironment (TME) is a critical focus for biomarker discovery and therapeutic targeting in cancer. However, widespread clinical adoption of TME profiling is hindered by the high cost and technical complexity of current platforms such as spatial transcriptomics and proteomics. Artificial Intelligence (AI)-based analysis of the TME from routine Hematoxylin & Eosin (H&E)-stained pathology slides presents a promising alternative. Yet, most existing deep learning approaches depend on extensive high-quality single-cell or patch-level annotations, which are labor-intensive and costly to generate. To address these limitations, we previously introduced HistoTME, a weakly supervised deep learning framework that predicts the activity of cell type-specific transcriptomic signatures directly from whole slide H&E images of non-small cell lung cancer. This enables rapid, high throughput analysis of the TME composition from whole slide H&E images (WSI) without the need for segmenting and classifying individual cells. In this work, we present HistoTME-v2, a pan-cancer extension of HistoTME, applied across 25 solid tumor types, substantially broadening the scope of prior efforts. HistoTME-v2 demonstrates high accuracy for predicting cell type-specific transcriptomic signature activity from H&E images, achieving a median Pearson correlation of 0.61 with ground truth measurements in internal cross- validation on The Cancer Genome Atlas (TCGA), encompassing 7,586 WSIs, 6,901 patients, and 24 cancer types, and a median Pearson correlation of 0.53 on external validation datasets spanning 5,657 WSIs, 1,775 patients and 9 cancer types. Furthermore, HistoTME- v2 resolves the spatial distribution of key immune and stromal cell types, exhibiting strong spatial concordance with single-cell measurements derived from multiplex imaging (CODEX, IHC) as well as Visium spatial transcriptomics, spanning 259 WSI, 154 patients, and 7 cancer types. Overall, across both bulk and spatial settings, HistoTME-v2 significantly outperforms baselines, positioning it as a robust, interpretable and cost-efficient tool for TME profiling and advancing the integration of spatial biology into routine pathology workflows.
Open AccessTowards interpretable molecular and spatial analysis of the tumor microenvironment from digital histopathology images with HistoTME-v2
The tumor microenvironment (TME) is a critical focus for biomarker discovery and therapeutic targeting in cancer. However, widespread clinical adoption of TME profiling is hindered by the high cost and technical complexity of current platforms such as spatial transcriptomics and proteomics. Artificial Intelligence (AI)-based analysis of the TME from routine Hematoxylin & Eosin (H&E)-stained pathology slides presents a promising alternative. Yet, most existing deep learning approaches depend on extensive high-quality single-cell or patch-level annotations, which are labor-intensive and costly to generate. To address these limitations, we previously introduced HistoTME, a weakly supervised deep learning framework that predicts the activity of cell type-specific transcriptomic signatures directly from whole slide H&E images of non-small cell lung cancer. This enables rapid, high throughput analysis of the TME composition from whole slide H&E images (WSI) without the need for segmenting and classifying individual cells. In this work, we present HistoTME-v2, a pan-cancer extension of HistoTME, applied across 25 solid tumor types, substantially broadening the scope of prior efforts. HistoTME-v2 demonstrates high accuracy for predicting cell type-specific transcriptomic signature activity from H&E images, achieving a median Pearson correlation of 0.61 with ground truth measurements in internal cross- validation on The Cancer Genome Atlas (TCGA), encompassing 7,586 WSIs, 6,901 patients, and 24 cancer types, and a median Pearson correlation of 0.53 on external validation datasets spanning 5,657 WSIs, 1,775 patients and 9 cancer types. Furthermore, HistoTME- v2 resolves the spatial distribution of key immune and stromal cell types, exhibiting strong spatial concordance with single-cell measurements derived from multiplex imaging (CODEX, IHC) as well as Visium spatial transcriptomics, spanning 259 WSI, 154 patients, and 7 cancer types. Overall, across both bulk and spatial settings, HistoTME-v2 significantly outperforms baselines, positioning it as a robust, interpretable and cost-efficient tool for TME profiling and advancing the integration of spatial biology into routine pathology workflows.
- Open Access
- 9 January 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1
Author Correction: Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
- 9 January 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1
Open AccessAuthor Correction: Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
- Open Access
- 19 December 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-15
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel weakly supervised deep learning approach to infer the tumor microenvironment (TME) composition directly from histopathology images of NSCLC patients. We show that HistoTME accurately predicts the expression of 30 distinct cell type-specific molecular signatures directly from whole slide images, achieving an average Pearson correlation of 0.5 with the ground truth on independent tumor cohorts. Furthermore, we find that HistoTME-predicted microenvironment signatures and their underlying interactions improve prognostication of lung cancer patients receiving immunotherapy, achieving an AUROC of 0.75 [95% CI: 0.61-0.88] for predicting treatment responses following first-line ICI treatment, utilizing an external clinical cohort of 652 patients. Collectively, HistoTME presents an effective approach for interrogating the TME and predicting ICI response, complementing PD-L1 expression, and bringing us closer to personalized immuno-oncology.
- 19 December 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-15
Open AccessPredicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel weakly supervised deep learning approach to infer the tumor microenvironment (TME) composition directly from histopathology images of NSCLC patients. We show that HistoTME accurately predicts the expression of 30 distinct cell type-specific molecular signatures directly from whole slide images, achieving an average Pearson correlation of 0.5 with the ground truth on independent tumor cohorts. Furthermore, we find that HistoTME-predicted microenvironment signatures and their underlying interactions improve prognostication of lung cancer patients receiving immunotherapy, achieving an AUROC of 0.75 [95% CI: 0.61-0.88] for predicting treatment responses following first-line ICI treatment, utilizing an external clinical cohort of 652 patients. Collectively, HistoTME presents an effective approach for interrogating the TME and predicting ICI response, complementing PD-L1 expression, and bringing us closer to personalized immuno-oncology.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) Macrophage density (number of CD204 positive cells per mm2) outputs for each case that passed quality review.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) Macrophage density (number of CD204 positive cells per mm2) outputs for each case that passed quality review.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
Purpose:Osteosarcoma is an aggressive bone cancer lacking robust biomarkers for personalized treatment. Despite its scarcity in humans, it is relatively common in adult pet dogs. This study aimed to analyze clinically annotated bulk tumor transcriptomic datasets of canine and patients with human osteosarcoma to identify potentially conserved patterns of disease progression.Experimental Design:Bulk transcriptomic data from 245 pet dogs with treatment-naïve appendicular osteosarcoma were analyzed using deconvolution to characterize the tumor microenvironment (TME). The TME of both primary and metastatic tumors derived from the same dog was compared, and its impact on canine survival was assessed. A machine learning model was developed to classify the TME based on its inferred composition using canine tumor data. This model was applied to eight independent human osteosarcoma datasets to assess its generalizability and prognostic value.Results:This study found three distinct TME subtypes of canine osteosarcoma based on cell type composition of bulk tumor samples: immune enriched, immune enriched dense extracellular matrix-like, and immune desert. These three TME-based subtypes of canine osteosarcomas were conserved in humans and could predict progression-free survival outcomes of human patients, independent of conventional prognostic factors such as percent tumor necrosis post standard of care chemotherapy treatment and disease stage at diagnosis.Conclusions:These findings demonstrate the potential of leveraging data from naturally occurring cancers in canines to model the complexity of the human osteosarcoma TME, offering a promising avenue for the discovery of novel biomarkers and developing more effective precision oncology treatments.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
Purpose:Osteosarcoma is an aggressive bone cancer lacking robust biomarkers for personalized treatment. Despite its scarcity in humans, it is relatively common in adult pet dogs. This study aimed to analyze clinically annotated bulk tumor transcriptomic datasets of canine and patients with human osteosarcoma to identify potentially conserved patterns of disease progression.Experimental Design:Bulk transcriptomic data from 245 pet dogs with treatment-naïve appendicular osteosarcoma were analyzed using deconvolution to characterize the tumor microenvironment (TME). The TME of both primary and metastatic tumors derived from the same dog was compared, and its impact on canine survival was assessed. A machine learning model was developed to classify the TME based on its inferred composition using canine tumor data. This model was applied to eight independent human osteosarcoma datasets to assess its generalizability and prognostic value.Results:This study found three distinct TME subtypes of canine osteosarcoma based on cell type composition of bulk tumor samples: immune enriched, immune enriched dense extracellular matrix-like, and immune desert. These three TME-based subtypes of canine osteosarcomas were conserved in humans and could predict progression-free survival outcomes of human patients, independent of conventional prognostic factors such as percent tumor necrosis post standard of care chemotherapy treatment and disease stage at diagnosis.Conclusions:These findings demonstrate the potential of leveraging data from naturally occurring cancers in canines to model the complexity of the human osteosarcoma TME, offering a promising avenue for the discovery of novel biomarkers and developing more effective precision oncology treatments.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
Gene set enrichment analysis results of cancer Hallmark pathways enriched in the IE (Immune Enriched) TME subtype
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
Gene set enrichment analysis results of cancer Hallmark pathways enriched in the IE (Immune Enriched) TME subtype
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) T cell density (number of CD3 positive cells per mm2) outputs for each case that passed quality review.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) T cell density (number of CD3 positive cells per mm2) outputs for each case that passed quality review.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) Collagen quantification (%Positive Masson’s Trichrome area) outputs for each case that passed quality review.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes
QuPath (v0.5.0) Collagen quantification (%Positive Masson’s Trichrome area) outputs for each case that passed quality review.